Printer Friendly

CURAFLEX AWARDED PATENT FOR TREATMENT OF SEVERE MALNUTRITION ASSOCIATED WITH CHRONIC LUNG DISEASES

 ONTARIO, Canada, June 24 /PRNewswire/ -- Curaflex Health Services, Inc. (NASDAQ: CFLX) announced today that the company has been issued United States Patent Number 5,179,080 for a method of treating malnutrition in chronic lung disease patients with a formulation containing human pituitary growth hormone (hGH) and nutritional supplements.
 This method was developed by Michael Rothkopf, M.D., Senior Vice President, Clinical Affairs for Curaflex. Dr. Rothkopf was a co- founder of Clinical Homecare Ltd., a home infusion therapy company which merged with Curaflex in March 1993, and currently provides specialized treatment to patients at the company's Fairfield, N.J. regional infusion therapy center. He received his M.D. from Eastern Virginia Medical School in Norfolk, Va., and his B.A. from Syracuse University. In addition, Dr. Rothkopf was a Fellow in Nutrition and Metabolism at Columbia Presbyterian Hospital.
 An estimated 2 million people in the U.S. currently suffer from such chronic lung diseases as emphysema and interstitial fibrosis. The company estimates that 50,000 patients die each year from these diseases. Approximately 50 percent of these patients are found to be severely malnourished, and could benefit from Dr. Rothkopf's method of nutritional replacement. Curaflex has developed a strategy to work closely with pulmonologists and patients who have severe malnutrition associated with pulmonary disease.
 Dr. Rothkopf commented: "Our research explores an approach for treating severe malnutrition using hormonal manipulation in combination with state-of-the-art nutritional support. Our goal is to recover a patient's nutrition status faster than has previously been possible with standard care. In the current study, we were able to prove that hGH accelerated the nutrition process through a change in metabolic status of the patient. In effect, we made the body utilize the nutrients more effectively through the use of hGH."
 The treatment consisted of the concurrent administration of hGH, a metabolically active peptide, and a nutritional supplement including proteins, carbohydrates, fats, electrolytes and vitamins. This combination was found to substantially improve the recovery from severe malnutrition in patients with chronic lung disease. The nutritional supplement was administered to match the specific metabolic needs of the patient by measuring resting energy expenditure (REE), substrate oxidation and nitrogen output.
 It was found that this administration significantly increased the nitrogen balance, decreased the respiratory quotient and enhanced fat oxidation while reducing carbohydrate oxidation, thereby providing a technique for refeeding patients without increasing metabolic demands and ventilatory requirements.
 Curaflex Health Services, Inc. is a national provider of comprehensive infusion therapy and related services to patients in the home and alternate site environments. Its home infusion therapy operations include regional centers and satellite facilities strategically located in major U.S. markets. The Company also provides infusion therapy as part of a broader program of clinical care, at disease-specific outpatient centers focusing on the treatment of complex long-term diseases.
 -0- 6/24/93
 /CONTACT: Robert Borchert or Eileen English of Morgen-Walke Associates, 212-850-5600, for Curaflex/
 (CFLX)


CO: Curaflex Health Services, Inc. ST: California IN: MTC SU:

MG -- NYTH004 -- 5142 06/24/93 08:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:503
Previous Article:NEW SERVICE HELPS ANYONE LEASE ANY VEHICLE WITH THE INFORMATION, SOURCES DEALERS HAVE
Next Article:OSTEOTECH ANNOUNCES BROAD EUROPEAN AND U.S. VENTURE WITH APS-MATERIALS TO EXPAND ORTHOPAEDIC AND DENTAL COATING SERVICES
Topics:


Related Articles
TELIOS ANNOUNCES SBIR GRANT FOR DECORIN
ALPHA 1 ACQUIRES PATENT RIGHTS FOR USE OF THYMOSIN TO TREAT LUNG CANCERS
PATHOGENESIS COMPLETES PATIENT ENROLLMENT FOR PHASE III TRIAL IN CYSTIC FIBROSIS PATIENTS
Therapeutics 2000, Inc. to License Respiratory Products to Adams Laboratories, Inc.
PathoGenesis Corp. Begins Clinical Trial of TOBI in Patients with Severe Bronchiectasis.
Incara announces issuance of patent on liver precursor cell.
FDA Approves New Treatment for Serious Lung Disease; Advair Diskus(R) 250/50 (fluticasone propionate 250 mcg and salmeterol 50 mcg inhalation powder)...
Chiron announces settlement of patent dispute over tobramycin solution.
Inhaled Bronchodilators Confirmed as a Preferred Maintenance Therapy in Managing Chronic Obstructive Pulmonary Disease (COPD); - Current Approaches...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters